UK markets close in 4 hours 13 minutes


Dusseldorf - Dusseldorf Delayed price. Currency in EUR
Add to watchlist
157.35+2.00 (+1.29%)
As of 12:30PM CEST. Market open.
Full screen
Previous close155.35
Bid157.30 x 0
Ask157.35 x 0
Day's range155.40 - 157.35
52-week range99.86 - 157.35
Avg. volume53
Market capN/A
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • This New Product Is Central to mRNA Vaccines -- But Should You Buy the Stock?
    Motley Fool

    This New Product Is Central to mRNA Vaccines -- But Should You Buy the Stock?

    Will the timely new product position Merck KGaA as an upstream supplier for the entire mRNA medicine world and allow it to reap the benefits, or is it unlikely to reward shareholders? To start, let's quickly review the scientific concepts at hand so that it's clear why Merck KGaA's new product is worth knowing about. As you may know, lipid molecules don't dissolve in water.

  • Reuters

    Lab supplier Merck KGaA says U.S. Defense Production Act poses challenge

    FRANKFURT (Reuters) -Merck KGaA on Wednesday said that U.S. regulations that give priority to U.S. government contracts to purchase COVID-19 vaccines are a challenge as it seeks to meet soaring demand for its lab equipment and supplies across the globe. She said U.S. law required that a preference be given to so-called rated state orders for COVID-19 programmes over any other orders. "For us, all our customers and all the other COVID-19 programmes are very crucial and we are making capacity expansion a top priority of our agenda," she said, pointing to investment projects both in the United States and Europe.

  • EQS Group

    Merck KGaA raises forecast for full year 2021

    Merck KGaA / Key word(s): Forecast/Change in ForecastMerck KGaA raises forecast for full year 202104-May-2021 / 20:36 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.Darmstadt, 4 May 2021. Based on high demand expected to continue throughout the year and a very strong first quarter of 2021 with net sales of EUR 4.63 bn resulting in EBITDA pre1 of EUR 1.51 bn and EPS pre1 of EUR 2.18, Merck KGaA (the "Company") has raised its forecast for the entire group for fiscal 2021. The Company now projects net sales of approx. EUR 18.5 - 19.5 bn (previously "strong organic growth"). EBITDA pre1 is anticipated to grow to approx. EUR 5.4 - 5.8 bn for the group (previously "organic: high single-digit to low teens growth"). EPS pre1 is projected to amount to approx. EUR 7.50 - 8.20.The Company will publish first-quarter 2021 figures as scheduled on 12 May 2021.1 EBITDA pre and EPS pre are alternative performance measures not defined by international accounting standards, used by the Company to improve the comparability of business performance over time and within the industry. EBITDA pre means earnings before interest, income tax, depreciation and amortization as well as adjustments (Ergebnis vor Zinsen, Ertragsteuern, Abschreibungen und Anpassungen). EPS pre means profit after tax including adjustments per theoretical shares outstanding (see Merck Annual Report 2020). Contact:Andreas Cezanne, Head of Corporate Media Relations04-May-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at Language: English Company: Merck KGaA Frankfurter Str. 250 64293 Darmstadt Germany Phone: +49 (0)6151 72 - 2702 E-mail: Internet: ISIN: DE0006599905 WKN: 659990 Indices: DAX Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; London, SIX EQS News ID: 1192510 End of Announcement DGAP News Service